[F:1][C:2]1([F:8])[CH2:4][CH:3]1[C:5](O)=[O:6].C1C=CC2N(O)N=NC=2C=1.C(Cl)CCl.C(=O)(O)[O-].[Na+].[O:28]1[CH2:33][CH2:32][N:31]([CH2:34][C:35]2[CH:36]=[CH:37][C:38]3[N:42]=[C:41]([C:43]4[C:51]5[C:46](=[CH:47][CH:48]=[C:49]([NH2:52])[CH:50]=5)[N:45]([CH:53]5[CH2:58][CH2:57][CH2:56][CH2:55][O:54]5)[N:44]=4)[NH:40][C:39]=3[CH:59]=2)[CH2:30][CH2:29]1>CN(C=O)C>[F:1][C:2]1([F:8])[CH2:4][CH:3]1[C:5]([NH:52][C:49]1[CH:50]=[C:51]2[C:46](=[CH:47][CH:48]=1)[N:45]([CH:53]1[CH2:58][CH2:57][CH2:56][CH2:55][O:54]1)[N:44]=[C:43]2[C:41]1[NH:42][C:38]2[CH:37]=[CH:36][C:35]([CH2:34][N:31]3[CH2:32][CH2:33][O:28][CH2:29][CH2:30]3)=[CH:59][C:39]=2[N:40]=1)=[O:6]2,2-Difluorocyclopropane carboxylic acid (3 mg, 0.024 mmol), HOBt (5 mg, 0.037 mmol), EDC (6.6 mg, 0.035 mmol) and sodium bicarbonate (2 mg, 0.024 mmol) were added to a solution of 3-(6-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (10 mg, 0.023 mmol) in DMF (5 mL). The reaction mixture was stirred at room temperature for 24 h, and then the solvent was removed in vacuo. Purification by flash chromatography (6% CH3OH/CH2Cl2) yielded the title compound (10 mg) as a solid. 1H NMR: (400 MHz, CD3OD): δ 8.62 (s, 1H), 7.75-7.66 (m, 4H), 7.34 (d, 1H, J=8.0 Hz), 5.94 (dd, 1H, J=2.8 and 9.6 Hz), 4.01 (m, 3H), 3.85 (m, 1H), 3.77 (m, 4H), 2.81 (m, 4H), 2.68 (m, 1H), 2.18-2.10 (m, 3H), 1.91-1.83 (m, 3H), 1.71 (m, 2H); ESI-MS [M+H]+: 537.2.
Wird geladen…